by Rod Raynovich | Mar 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Quest Diagnostics said today it would buy the diagnostics company Celera (CRA $8.10) for $671M.Celera business momentum had stalled in 2010 with Q4 Revenue down 11% at $34.9M with Net Income at 3 cents a share down from 4 cents a share in Q4 2009. Results from...
by Rod Raynovich | Mar 17, 2011 | 2024-25 Life Science Portfolios, BIOgraph
M&A Target?? Molecular diagnostic device maker was a mover today on low volume with an analyst initiation at outperform.The stock is near its recent 52 week high of $27.79. Cepheid is an emerging growth leader in molecular diagnostics with its GeneXpert platform...
by Rod Raynovich | Mar 15, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Volatile Day on Wall Street-Biotech Stocks Are Holding Up Well with NASDAQ Down 1.18% Selected biotech stocks were in the green today responding to good news despite a nasty day in the market. The major ETF’s were down FBT ($38 down 1.09%), IBB ($94.25 down...
by Rod Raynovich | Mar 10, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Sell-Off is Broad and 50 Day Moving Average is Breached on S&P The biotech sector could not take a cue from Dendreon (DNDN) and Human Genome Sciences (HGSI) good news and sold off more than 2% with MO names even more.The NASDAQ was down 1.84% and Bio ETF’s...
by Rod Raynovich | Mar 9, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Cubist(CBST) is up 5% today on heavy volume of 1.2M shares on no apparent news.52 week high is $25.48.On Monday the stock was $21.5. Maybe there is news on the TEVA lawsuit. CBST has a compelling valuation with ~$900M in cash and forecasted revenues of $688M, EPS of...
by Rod Raynovich | Mar 8, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Paired Trade Opportunity: Sell Vertex, Buy Cephalon Vertex (VRTX) is one of the hottest large cap biotech stocks based on FDA approval (May 23 review) of its lead drug candidate Telaprevir, an oral HCV protease inhibitor. The stock is off its highs of $52+in early...
by Rod Raynovich | Mar 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Speculative Small Cap Stocks Have Sold Off Since January 3 The Russell 2000 (IWM) was up 5% YTD but the index is down 2.3% today. The NASDAQ is down 2% as of 1:30p EST.Small Cap stocks have outperformed in 2011 so today’s sell off may be a caution signal....
by Rod Raynovich | Mar 3, 2011 | 2024-25 Life Science Portfolios, BIOgraph
2011 Update It looks like the mini-correction is over. Many stocks in our model portfolio are up 5% and more since 12/31/10 but we are still below peak values of mid-January . Laggards are CEPH, MITI and NKTR. Look at doubling down on Cephalon (CEPH) which is at its...
by Rod Raynovich | Feb 23, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotech ETF’s and Major Indices are 5% off mid-January highs NADAQ stocks sold off for a second day but biotechnology stocks were mixed with a few winners.Major biotech ETF’s were down about 0.75% and off 5% from their 2011 highs in mid-January, the...
by Rod Raynovich | Feb 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
BIO CEO and Investor Conference Feb 14-15 Biotechnology stocks picked up some buying interest today from the BIO CEO Conference in NYC. CNBC provided some CEO clips from Exelixis (EXEL $10.58) up 7%, Onyxx(ONXX $36.28) up 0.28% and Optimer (OPTR $11.61) up 2.83%....
